Biotech Investment News: Major Gilead Deals Over the Past Decade (2015–2025)
Strategic Review: Shifting from Antivirals to Oncology and Cell Therapy Gilead Sciences, once dominant in the antiviral space—particularly in HIV and hepatitis C—has been facing declining revenue due to patent cliffs. Since 2015, the com...
